Latest Breaking News On - Joel naor - Page 1 : comparemela.com

Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

BEDFORD, Mass., June 05, 2023 Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and. | June 5, 2023

Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights

30.08.2022 - Secured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations with appointment of C-Suite Executives Elected . Seite 1

Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief ...

Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD